

Anti-CD40L [hu5c8 (Ruplizumab)] Standard Size Ab00447-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar with an Fc Silent mutation.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: hu5c8 (Ruplizumab)

Alternative Name(s) of Target: CD154; CD40 ligand; tumour necrosis factor ligand superfamily member 5; TNFSF5; tumour necrosis factor related activation protein; TRAP

UniProt Accession Number of Target Protein: P29965

Published Application(s): WB, Block, FC

Published Species Reactivity: Human

Immunogen: Human CD40L

Specificity: The antibody binds to CD40L with an IC50 of 0.845 ug/ml.

Application Notes: The antibody binds specifically to CD40L, a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. The antibody neutralises CD40L function, as it blocks the interaction between CD40 and CD40L. When injected into cynomolgus monkeys, the original therapeutic antibody was found to have a T1/2 of 531 ± 155 hours.

Antibody First Published in: Karpusas et al. Structure of CD40 Ligand in Complex with the Fab Fragment of a Neutralizing Humanized Antibody Structure. 2001 Apr 4;9(4):321-9. [PMID:11525169](#)

Note on publication: Describes the role of CD40-CD40L interaction in immune responses and pathologies. Also describes the generation of humanized monoclonal antibodies against CD40L and the use of a crystal structure to determine its binding.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.